Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash from Financing Activities data on file, last reported at $96.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 79.59% year-over-year to $96.6 million in Q1 2026; TTM through Mar 2026 was $101.3 million, a 78.82% decrease from a year earlier, with the FY2025 full-year figure at $478.0 million, up 6079.54% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $96.6 million, up from $1.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for BEAM reached as high as $473.4 million in Q1 2025 and fell as low as $133000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $57.1 million across 5 years, with a median of $22.3 million in 2022.
• Across the five-year window, Cash from Financing Activities plunged 99.88% in 2024 and surged 16240.32% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $32.0 million in 2022, then climbed by 5.31% to $33.7 million in 2023, then plunged by 89.78% to $3.4 million in 2024, then sank by 45.24% to $1.9 million in 2025, then jumped by 5022.38% to $96.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $96.6 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.